Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Lucretius who wrote (279930)	3/12/2004 1:35:32 PM
From: Bid Buster	Read Replies (1) \| Respond to of 436258

This sucks even more, my calls are now underwater!

To: Lucretius who wrote (279930)	3/12/2004 2:46:43 PM
From: MythMan	Read Replies (2) \| Respond to of 436258

RealCommentary from TheStreet.com Reason Returns to the Market Friday March 12, 2:37 pm ET By James J. Cramer, RealMoney Columnist Looking for signs that the craziness -- that the economy is slowing dramatically, as the bond suggests -- is now past us, I spy the declines in Pepsi (NYSE:PEP - News), Coke (NYSE:KO - News) and Pfizer (NYSE:PFE - News). All three are important tells because all three either have had good news recently or have it in front of us. Pepsi recently reported a stellar quarter and the stock jumped to north of $52. It now is struggling to stay above $50. That screams, "No slowdown." Coke's got what should be a great quarter coming, as is often the case when you have a retiring CEO. I think that the quarter's "in the bag," yet the stock declined a couple of points Thursday and is down again today. Finally, there is Pfizer. The takes in Pfizer at $37 were gigantic and the stock looked like it could challenge General Electric (NYSE:GE - News) for largest-capitalized company (GE helped out by sending its stock down with an offering, but that still counts for capitalization.) The stunning news that Bristol-Myers Squibb (NYSE:BMY - News) paid for a study that benefited Pfizer was the kind of irony people love investing in.